OP0088 Immune-related adverse events of cancer immunotherapy – when inflammatory side effects are associated with survival: a single-centre prospective cohort study
Marie Kostine(Hôpital Cardiologique du Haut-Lévêque), Thierry Schaeverbeke(Inserm), M. Gross-Goupil(Bordeaux Population Health), Julie Lallier(Centre Hospitalier Universitaire de Bordeaux), Marie‐Elise Truchetet(Centre National de la Recherche Scientifique), Alain Ravaud(Bordeaux Population Health), Florent Martin(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Eleonora Mauric(Université de Bordeaux), Christophe Richez(Boston University), B Bannwarth(Centre Hospitalier Universitaire de Bordeaux), Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), Thomas Barnetche(Université de Bordeaux), Amaury Daste(Centre Hospitalier Universitaire de Bordeaux), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), L. Dousset(Centre Hospitalier Universitaire de Bordeaux), Nadia Mehsen-Cêtre(Bordeaux Population Health), M. Beylot‐Barry, L. Rouxel(Centre Hospitalier Universitaire de Bordeaux), S. Prey(Centre Hospitalier Universitaire de Bordeaux)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k